Limbic Encephalitis Manifesting as Selective Amnesia and Seizure-like Activity: A Case Report

So-Yeon KIM; Yoo-Hyun UM; Sung-Chul LIM; Jong-Hyun JEONG.
Clinical Psychopharmacology and Neuroscience ; : 109-113, 2018.
Artículo en Inglés | WPRIM | ID: wpr-739454

Documentos relacionados

  1. Binding Interactions of Ergotamine and Dihydroergotamine to 5-Hydroxytryptamine Receptor 1B (5-HT<sub>1b</sub>) Using Molecular Dynamics Simulations and Dynamic Network Analysis.
  2. Drug Repurposing to Inhibit Histamine <i>N</i>-Methyl Transferase.
  3. Dihydroergotamine mesylate nasal spray: an acute treatment option for migraine in adults.
  4. STOP 301: A Phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD<sup>®</sup> ) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients.
  5. A Phase 1, Randomized, Open-Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects.
  6. Dihydroergotamine (DHE) - Then and Now: A Narrative Review.
  7. Dihydroergotamine extravasation: prolonged arterial vasospasm requiring medical and surgical treatment.
  8. A randomized, open-label, 5-period crossover study evaluating the pharmacokinetics and safety of a single dose of intranasal dihydroergotamine (DHE) powder (STS101), intramuscular DHE mesylate, and liquid nasal spray DHE in healthy adults.
  9. The status of intravenous dihydroergotamine for pediatric headache: Status migrainosus and beyond.
  10. Implementation of an Intravenous Dihydroergotamine Protocol for Refractory Migraine in Children.